Associated Papers
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
Della Corte CM et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2022
35346313 (PubMed )
Supplement: 13046_2022_2332_MOESM3_ESM.xlsx › Foglio1
Select a paper to view details